Reported Earlier, Telix Reports Q3 2026 Group Revenue Of $245M, Up 19% YoY, With Precision Medicine Revenue Up 30% YoY To $201M On Gozellix And Illuccix Demand
Share
Why It Matters
Telix made more money this quarter than last year. Their medicine business grew especially fast, which shows customers want their products.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.